Independent pharmacies typically sell for 3x–5.5x EBITDA, but prescription file value, PBM contract terms, and specialty services can significantly move your final number. Here is how buyers think about pharmacy valuations in today's market.
Find Pharmacy Businesses For SaleIndependent pharmacies are primarily valued on a multiple of adjusted EBITDA, with the prescription file treated as a distinct asset often valued separately based on active patient count, 30-day refill rates, and revenue per patient. Buyers apply multiples of 3x–5.5x EBITDA depending on margin quality, revenue mix, compliance history, and the degree to which the business can operate without the owner-pharmacist. Specialty, compounding, and long-term care pharmacies command premiums at the higher end of that range due to their reduced PBM dependency and more predictable, recurring revenue streams.
3×
Low EBITDA Multiple
4.25×
Mid EBITDA Multiple
5.5×
High EBITDA Multiple
Pharmacies at the low end of the range typically have heavy concentration in low-margin generic prescriptions, significant DIR fee exposure, declining patient counts, or compliance concerns with DEA or state pharmacy boards. Mid-range valuations reflect solid prescription volume, stable EBITDA margins of 8–12%, and a transferable patient base with a licensed pharmacist willing to stay post-close. Premium multiples of 5x–5.5x are reserved for pharmacies with specialty or compounding revenue, long-term care or hospice contracts, clean regulatory histories, and documented systems that reduce key-person dependency on the owner.
$2,400,000
Revenue
$288,000
EBITDA
4.5x
Multiple
$1,296,000
Price
Asset purchase structured as $900,000 SBA 7(a) loan (70%), $180,000 seller carry note at 6% over 5 years (14%), and $216,000 buyer equity injection (16%). Prescription file and goodwill included in the asset purchase price. Inventory of approximately $85,000 priced separately at cost and added to the total consideration at closing. A 12-month earnout of up to $75,000 tied to retention of 80% of active patient prescription volume post-close, with seller providing a 90-day transition period working alongside the acquiring pharmacist.
EBITDA Multiple Method
The most common valuation approach for independent pharmacies. A buyer calculates adjusted EBITDA by adding back owner compensation, one-time expenses, and personal perks to net income, then applies a market multiple of 3x–5.5x. The resulting enterprise value is the starting point for deal negotiations. Buyers will scrutinize reimbursement trends, DIR fee history, and payer mix when selecting where in the range to peg the multiple.
Best for: Established pharmacies with $1M–$5M in revenue, positive EBITDA margins, and at least 2–3 years of consistent financial performance
Prescription File Valuation
Prescription files are often valued independently based on active patient count, average prescriptions per patient per year, revenue per prescription, and 30-day refill retention rates. Buyers may pay $8–$25 per active prescription file depending on drug mix, payer profile, and patient loyalty. This method is particularly relevant in asset purchase transactions where the prescription database is the primary asset being acquired.
Best for: Asset purchases where the buyer is acquiring patient files and inventory rather than the legal entity, or where EBITDA is low but the patient base is strong and transferable
Revenue Multiple Method
Pharmacy acquisitions occasionally reference revenue multiples, typically in the range of 0.3x–0.7x trailing twelve-month revenue. This method is most useful as a sanity check alongside EBITDA analysis, particularly for pharmacies with compressed margins where EBITDA-based valuations produce unrealistically low numbers that do not reflect the strategic value of the patient base or geographic location.
Best for: Early-stage valuation benchmarking, compounding or specialty pharmacies with below-average EBITDA due to high labor costs but strong revenue growth trajectories
High Active Patient Count With Strong Refill Rates
A pharmacy with 2,000+ active patients and 30-day refill rates above 60% demonstrates predictable, recurring prescription revenue that buyers can underwrite with confidence. High refill retention signals patient loyalty and reduces the risk of volume loss during ownership transition, which is the primary concern for any buyer underwriting a prescription file acquisition.
Specialty or Compounding Revenue Mix
Pharmacies generating 20% or more of revenue from compounding, specialty medications, or medication therapy management command premium multiples because these services operate outside standard PBM reimbursement structures. Higher gross margins on compounding and specialty fills directly improve EBITDA and make the business more resilient to ongoing reimbursement rate compression from PBMs.
Long-Term Care, Hospice, or Institutional Contracts
Contracts with long-term care facilities, assisted living communities, hospice organizations, or employer groups provide recurring, predictable prescription volume that is far more defensible than walk-in retail traffic. Buyers view these contracts as a significant risk buffer and will pay meaningfully higher multiples for pharmacies with two or more institutional relationships in place.
Clean DEA and State Board Compliance Record
A pharmacy with no DEA violations, state board investigations, or adverse audit findings from CMS or PBMs transfers cleanly and avoids the licensing delays that kill or restructure deals. Buyers and their lenders require a clear compliance history to approve financing, and any open regulatory matter will either reduce price or require escrowed proceeds until resolution.
Licensed Pharmacist Staff Willing to Stay Post-Close
Pharmacies where a staff pharmacist or pharmacy manager is willing to remain through and beyond the ownership transition are dramatically easier to finance and operate post-close. SBA lenders and PE buyers alike require evidence that licensed personnel can maintain operations independently of the selling owner. Documented employment agreements or transition commitments add measurable value.
Documented, Transferable Operating Systems
Pharmacies with written standard operating procedures, documented workflows for dispensing, billing, and payer reconciliation, and clean accounts receivable aging from third-party payers signal a professionally run operation. Buyers pay a premium for businesses that do not rely entirely on the owner's institutional knowledge to function, reducing transition risk and justifying higher multiples.
Heavy PBM Dependency and DIR Fee Exposure
Pharmacies where 85% or more of revenue flows through two or three PBM contracts with significant DIR fee clawbacks face unpredictable profitability that makes it difficult for buyers to underwrite a stable EBITDA figure. Buyers will apply deep discounts or require earnout structures to account for reimbursement deterioration risk, particularly if the pharmacy lacks specialty or compounding revenue to offset margin compression.
DEA Violations or State Board Investigations
Any open or recent DEA investigation, controlled substance compliance failure, or state pharmacy board disciplinary action is a deal-stopper for most buyers. Even resolved violations require extended due diligence and may trigger SBA lender requirements for escrow holdbacks. Buyers acquiring a pharmacy with a compliance blemish inherit reputational and operational risk that most will price in aggressively or walk away from entirely.
Owner-Operator With No Pharmacist Succession Plan
When the selling pharmacist is the only licensed pharmacist on staff and has no successor in place, buyers face an immediate operational gap at close. SBA lenders require a licensed pharmacist to be in place for loan approval, and the inability to retain or recruit a replacement pharmacist in a tight labor market can unravel a transaction or force the buyer to accept punitive earnout terms tied to staffing outcomes.
Declining Prescription Volume and Patient Attrition
A pharmacy showing 10% or more year-over-year decline in active patient count or total prescription volume signals competitive pressure, payer network losses, or demographic shifts in the service area. Buyers price declining trend lines into their offer using a discounted trailing period and will apply the lowest possible multiple, or structure the deal as a full earnout contingent on volume stabilization.
Revenue Concentration in a Single Payer or Employer Group
Pharmacies deriving more than 40% of revenue from a single payer contract, preferred network, or employer group face binary risk if that relationship is disrupted post-close. Change-of-ownership provisions in PBM contracts can trigger re-credentialing requirements or preferred network disqualification, and buyers will either demand significant price reductions or require seller escrow to cover the risk of payer contract loss.
Inventory and Accounts Receivable Management Issues
Outdated, expired, or poorly documented inventory and uncollected accounts receivable from third-party payers reduce both the asset value and the credibility of the seller's financials. Buyers will conduct a physical inventory count and AR aging review as core due diligence steps, and any significant write-downs discovered during diligence will be deducted from the purchase price or used to renegotiate deal terms at closing.
Find Pharmacy Businesses For Sale
Signal-scored targets with seller motivation, multiples, and outreach — free to join.
Independent pharmacies are primarily valued using a multiple of adjusted EBITDA, typically ranging from 3x to 5.5x depending on the quality of earnings, patient base stability, payer mix, and compliance history. The prescription file is often valued as a separate asset based on active patient count and 30-day refill rates. Buyers will also review trailing revenue trends, PBM contract terms, DIR fee exposure, and staff pharmacist availability before settling on a final offer price.
Prescription files are typically valued at $8–$25 per active patient file, depending on refill retention rates, drug mix, payer profile, and how recently those patients filled a prescription. A pharmacy with 2,500 active patients and strong 30-day refill rates might price its prescription file at $20–$25 per file, representing $50,000–$62,500 in standalone prescription file value that is added to the overall business valuation or structured as a separate asset in an asset purchase agreement.
Yes, significantly. PBM reimbursement rates and DIR fee clawbacks directly impact your net EBITDA, which is the primary basis for valuation. A pharmacy heavily dependent on two or three PBM contracts with declining reimbursement rates will show compressed or declining EBITDA over time, which buyers will use to justify lower multiples and more conservative offer prices. Pharmacies that have diversified into compounding, specialty, or long-term care revenue command higher multiples precisely because they are less exposed to PBM rate pressure.
Yes. Independent pharmacy acquisitions are one of the more common SBA 7(a) loan use cases in the healthcare sector. SBA financing can cover up to 90% of the total acquisition cost including goodwill, prescription files, and equipment. To qualify, the buyer typically needs to be a licensed pharmacist or have a licensed pharmacist committed to running operations post-close. Sellers are often asked to carry a subordinated note of 10–20% of the purchase price to help bridge valuation gaps and satisfy lender requirements.
Buyers place the highest value on pharmacies with large active patient bases showing strong 30-day refill retention, specialty or compounding revenue that generates margins above standard PBM reimbursement rates, long-term care or institutional contracts providing recurring volume, clean DEA and state board compliance histories, and a licensed pharmacist staff member willing to stay post-close. Any combination of these factors reduces buyer risk and supports multiples at the higher end of the 3x–5.5x EBITDA range.
Most independent pharmacy sales take 12–24 months from initial preparation to closing. The process involves getting financials in order, engaging a pharmacy-specialized broker or M&A advisor, running a buyer search, completing due diligence, negotiating deal structure, and navigating DEA change-of-ownership registration, state pharmacy board approvals, and PBM re-credentialing. Sellers who begin preparation early, have clean compliance records, and have documented financials ready for buyer review tend to close closer to the 12-month end of that range.
Your DEA registration does not automatically transfer to a buyer. The acquiring pharmacist or entity must apply for a new DEA registration, and the DEA requires the previous registrant to surrender the existing registration upon completion of the sale. Many states also require state pharmacy board notification or approval prior to the change of ownership. Because this process can take 60–120 days or longer, it is critical to initiate DEA and state board transfer steps early in the transaction timeline to avoid closing delays or operational gaps.
An earnout is a contingent payment structure where the seller receives additional compensation after closing based on the pharmacy's performance against agreed-upon metrics. In pharmacy acquisitions, earnouts are most commonly tied to prescription volume retention or active patient count over a 12–24 month period following the sale. For example, a seller might receive a base payment at close with an additional $50,000–$100,000 payable if the pharmacy retains 80% or more of its active patient volume within 18 months post-close. Earnouts help bridge valuation gaps when buyers are uncertain about patient retention risk during ownership transition.
More Pharmacy Guides
DealFlow OS surfaces acquisition targets, scores seller motivation, and generates outreach — free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers